Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$6.63
-5.2%
$6.21
$4.02
$15.10
$359.88M2.091.73 million shs1.00 million shs
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$5.29
-5.5%
$5.09
$3.81
$29.30
$487.63M1.911.26 million shs1.38 million shs
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
$0.51
-2.9%
$0.54
$0.31
$3.18
$119.34M1.239.03 million shs2.53 million shs
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$9.79
-2.4%
$10.23
$5.83
$26.25
$409.52MN/A187,835 shs117,263 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
0.00%+10.17%+5.27%+57.68%-11.85%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.00%+6.67%+10.02%-30.61%-77.51%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
0.00%-0.91%+1.13%-24.18%+66.20%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
0.00%+4.70%-9.80%+29.42%+1,002,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
4.2891 of 5 stars
3.51.00.04.62.12.51.3
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
4.1191 of 5 stars
4.13.00.04.10.01.70.6
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
2.7026 of 5 stars
3.34.00.00.02.40.80.6
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
1.2019 of 5 stars
3.50.00.00.00.60.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
3.00
Buy$14.33116.19% Upside
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2.13
Hold$14.38171.92% Upside
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
2.67
Moderate Buy$4.50779.25% Upside
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
3.00
Buy$36.67274.53% Upside

Current Analyst Ratings Breakdown

Latest SGMO, MYGN, ZBIO, and EBS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/21/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.00
5/16/2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/15/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$12.50 ➝ $9.00
5/15/2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$35.00
5/14/2025
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$9.00 ➝ $5.00
5/8/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Peer Perform
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$18.00
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $8.00
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$19.00 ➝ $10.00
5/7/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $7.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$1.04B0.34$1.82 per share3.64$8.91 per share0.74
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$837.60M0.58$0.94 per share5.60$7.70 per share0.69
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
$57.80M2.06N/AN/A$0.11 per share4.65
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
$5M81.90N/AN/A$7.48 per share1.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
-$190.60M-$2.71N/A3.20N/A-13.63%-0.52%-0.17%8/5/2025 (Estimated)
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$127.30M-$1.12N/AN/AN/A-12.20%-4.95%-3.39%8/5/2025 (Estimated)
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
-$97.94M-$0.39N/AN/AN/A-124.61%-345.98%-79.86%8/5/2025 (Estimated)
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$156.99M-$3.55N/AN/AN/AN/AN/A8/21/2025 (Estimated)

Latest SGMO, MYGN, ZBIO, and EBS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
-$1.15-$0.80+$0.35-$0.80$5.00 million$10.00 million
5/12/2025Q1 2025
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
-$0.11-$0.14-$0.03-$0.14$7.90 million$6.44 million
5/7/2025Q1 2025
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$0.49$0.71+$0.22$1.19$218.50 million$222.20 million
5/6/2025Q1 2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$0.05-$0.03+$0.02N/A$200.37 million$195.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
N/AN/AN/AN/AN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
N/AN/AN/AN/AN/A
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
N/AN/AN/AN/AN/A
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
1.20
6.32
3.51
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.08
1.90
1.71
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
N/A
0.76
0.76
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A
6.47
6.47

Institutional Ownership

CompanyInstitutional Ownership
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
78.40%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
99.02%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
56.93%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A

Insider Ownership

CompanyInsider Ownership
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
3.20%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2.10%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
4.10%
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
16.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
2,42054.28 million52.54 millionOptionable
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2,70092.18 million90.24 millionOptionable
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
480233.17 million223.61 millionOptionable
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
N/A41.83 million34.93 millionN/A

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Emergent Biosolutions stock logo

Emergent Biosolutions NYSE:EBS

$6.63 -0.36 (-5.15%)
Closing price 03:59 PM Eastern
Extended Trading
$6.57 -0.06 (-0.90%)
As of 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Myriad Genetics stock logo

Myriad Genetics NASDAQ:MYGN

$5.29 -0.31 (-5.54%)
Closing price 04:00 PM Eastern
Extended Trading
$5.28 -0.01 (-0.17%)
As of 05:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Sangamo Therapeutics stock logo

Sangamo Therapeutics NASDAQ:SGMO

$0.51 -0.02 (-2.87%)
Closing price 04:00 PM Eastern
Extended Trading
$0.52 +0.01 (+1.21%)
As of 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Zenas BioPharma stock logo

Zenas BioPharma NASDAQ:ZBIO

$9.79 -0.24 (-2.39%)
As of 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.